Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines

## Authors

Noriyuki Nakatsu, Tomoki Nakamura, Kanami Yamazaki, Soutaro Sadahiro, Hiroyasu Makuuchi, Jun Kanno, and Takao Yamori.

## Affiliations

Division of Molecular Pharmacology (N. N., T. N., K. Y., T. Y.), Cancer Chemotherapy Center, Japanese

Foundation for Cancer Research, Koto-ku, Tokyo 135-8550, Japan

Division of Cellular and Molecular Toxicology (N. N., J. K.), Biological Safety Research Center, National Institute of Health Sciences, Setagaya-ku, Tokyo 158-8501, Japan

Second Department of Surgery (T. N., S. S., H. M.), Tokai University School of Medicine, Boseidai, Isehara-City, Kanagawa 259-1193, Japan

## Running Title:

Evaluation of toxic chemicals using JFCR39

## Corresponding author

Takao Yamori
Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, Japan.
Phone: 81-3-3520-0111
Fax: 81-3-3570-0484
E-mail: yamori@jfcr.or.jp

The number of
text pages 26
tables 2 (5)
figures 3
references 25

## The number of words in

Abstract 239
Introduction 452
Discussion 790

## Nonstandard abbreviations

GI50: 50\% growth inhibition concentration

## Abstract

We previously established a panel of human cancer cell lines, JFCR39, coupled to an anti-cancer drug
activity database; this panel is comparable to the NCI60 panel developed by the National Cancer Institute. The JFCR39 system can be used to predict the molecular targets or evaluate the action mechanisms of the test compounds by comparing their cell growth inhibition profiles (i.e., fingerprints) with those of the standard anti-cancer drugs using the COMPARE program. In this study, we used this drug activity database-coupled JFCR39 system to evaluate the action mechanisms of various chemical compounds including toxic chemicals, agricultural chemicals, drugs, and synthetic intermediates. Fingerprints of 130 chemicals were determined and stored in the database. Sixty nine of 130 chemicals (approx. 60\%) satisfied our criteria for the further analysis, and were classified into the following three clusters by cluster analysis of the fingerprints of these chemicals and several standard anti-cancer drugs:

1) clusters consisted of only anti-cancer drugs, 2) clusters of chemicals which shared similar action mechanisms (for example, ouabain and digoxin), and 3) a cluster of chemicals whose action mechanisms
were unknown. These results suggested that chemicals belonging to a cluster (i.e., a cluster of toxic chemicals, a cluster of anti-cancer drugs etc.) shared similar action mechanism. In summary, the JFCR39 system can classify chemicals based on their fingerprints, even when their action mechanisms are unknown, and it is highly probable that the chemicals within a cluster share common action mechanisms.

## Introduction

Determining the action mechanism or identifying the molecular target of a chemical with pharmacological activity or adverse side effects is highly desirable. Although various test methods are currently available for determining the action mechanisms of chemicals, such as methods based on animal models, methods based on cellular models, bacterial mutagenicity test, the uterotrophic assay (Kanno et al., 2002), Hershberger test (Hershberger et al., 1953) and the reporter assay for the nuclear receptor agonists, determination of the action mechanisms of pharmacologically active chemicals, including the toxic chemicals, is still a difficult and challenging task. Therefore, it is highly desirable to develop efficient test methods for evaluating toxicity of chemicals.

A number of screening methods are currently available for discovering new anti-cancer drugs. One very powerful and unique approach using multiple cancer cell lines was developed at NCI (Paull et al., 1989; Weinstein et al., 1992; Weinstein et al., 1997) and also in our laboratory (Akashi et al., 2007; Akashi and Yamori, 2007; Dan et al., 2003; Dan et al., 2002; Nakamura et al., 2007; Nakatsu et al., 2005; Yamori, 2003; Yamori et al., 1999). This bioinformatics-based approach enables mechanism-oriented evaluation of anti-cancer drugs. For example, we can evaluate the cell toxicity in vitro by determining the $50 \%$ growth inhibition (GI50), total growth inhibition (TGI), and $50 \%$ lethal concentration (LC50) across a panel of 39 human cancer cell lines (JFCR39). We can also predict the molecular targets or evaluate the action mechanisms of the test compounds by comparing the cell growth

## MOL \#38836

inhibition profiles (termed fingerprint) across the panel for these compounds with those of the standard anti-cancer drugs using the COMPARE algorithm (Yamori et al., 1999). We have used this system successfully, and demonstrated that the molecular targets of the novel chemicals MS-274, FJ5002, and ZSTK474 were topoisomerases I and II (Yamori et al., 1999), telomerase (Naasani et al., 1999), and PI 3-kinase (Yaguchi et al., 2006), respectively. Several other interesting studies, based on a panel of cancer cells, classified anti-cancer drugs according to their action mechanism or molecular targets by cluster analysis of their GI50 values (Dan et al., 2002; Weinstein et al., 1992; Weinstein et al., 1997). Correlation analysis has also been used to explore the genes associated with the sensitivity of the cells in the panel to anti-cancer drugs (Nakatsu et al., 2005; Okutsu et al., 2002; Scherf et al., 2000; Zembutsu et al., 2002).

In this study, we have examined the potential of the JFCR39 system in classifying various chemicals, and predicted their action mechanisms. For this purpose, we have determined the fingerprints of 130 different types of chemicals including toxic chemicals, pesticides, drugs and synthetic intermediates, and then classified these chemicals according to the cluster analysis of their fingerprints.

## Material and Methods

Cell Lines and Cell Cultures. The panel of human cancer cell lines has been described previously (Dan et al., 2002; Yamori et al., 1999) and consists of the following 39 human cancer cell lines: lung cancer, NCI-H23, NCI-H226, NCI-H522, NCI-H460, A549, DMS273, and DMS114; colorectal cancer, HCC-2998, KM-12, HT-29, HCT-15, and HCT-116; gastric cancer, MKN-1, MKN-7, MKN-28, MKN-45, MKN-74, and St-4; ovarian cancer, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SK-OV-3; breast cancer, BSY-1, HBC-4, HBC-5, MDA-MB-231, and MCF-7; renal cancer, RXF-631L and ACHN; melanoma, LOX-IMVI; glioma, U251, SF-295, SF-539, SF-268, SNB-75, and SNB-78; and prostate cancer, DU-145 and PC-3. All cell lines were cultured in RPMI 1640 (Nissui Pharmaceutical, Tokyo, Japan) with 5\% fetal bovine serum, penicillin (100 units $/ \mathrm{mL}$ ), and streptomycin ( $100 \mu \mathrm{~g} / \mathrm{mL}$ ) at $37^{\circ} \mathrm{C}$ under $5 \% \mathrm{CO}_{2}$.

Determination of cell growth inhibition profiles. Growth inhibition experiments were performed to assess the sensitivity of the cells to various chemicals as described before (Dan et al., 2002; Yamori et al., 1999). Growth inhibition was measured by determining the changes in the amounts of total cellular protein after 48 hours of chemical treatment using a sulforhodamine B assay. For each chemical, the growth assay was performed using a total of five different concentrations of the chemical (for example,

## MOL \#38836

$10^{-4}, 10^{-5}, 10^{-6}, 10^{-7}$, and $\left.10^{-8} \mathrm{M}\right)$ and one negative control. All assays were performed in duplicate. This GI50 calculation method is well established and reliable through anti-cancer drug screen using NCI60 as well as JFCR39 (Paull et al., 1989; Yamori, 2003; Yamori et al., 1999). At each test concentration, the percentage growth was calculated using the following seven absorbance measurements: growth at time zero (T0), growth of the control cells (C), and test growth in the presence of five different concentrations (T) of a drug. The percentage growth inhibition was calculated as: $\%$ growth $=100 \times[(\mathrm{T}-\mathrm{T} 0) /(\mathrm{C}-\mathrm{T} 0)]$ when $\mathrm{T} \geq \mathrm{T} 0$, and $\%$ growth $=100 \times[(\mathrm{T}-\mathrm{T} 0) / \mathrm{T}]$ when $\mathrm{T}<\mathrm{T} 0$. The GI50 values, which represent $50 \%$ growth inhibition concentration, were calculated as $100 \times[(\mathrm{T}-\mathrm{T} 0) /(\mathrm{C}-\mathrm{T} 0)]=50$. When the GI50 of a chemical could not be calculated, the highest used concentration was assigned as its GI50 value. Absolute values of GI50 were then $\log$ transformed for further analysis. We certified the accuracy of measured GI50 data by using reference control chemicals, such as MMC, paclitaxel and SN-38, every experiment and by checking the dose response curves.

Chemicals. Spironolactone, para-aminoazobenzene, para-cresidine, neostigmin bromide, para-dichlorobenzene, phenytoin, ortho-toluidine, imipramine, cobalt chloride, atrazine, propylthiouracil, (d,l) thalidomide, carbon tetrachloride, hydroquinone, monocrotaline, vinyl chloride, tributyl-tin chloride, valproic acid, benzene, acrylamide, pentachlorophenol, aniline, 1,3-diphenylguanidine, polypropylene glycol, 10,10'-oxy-bis(phenoxyarsine), testosterone propionate, carbaryl, acephate,

## MOL \#38836

bisphenol A, 17-beta-estradiol, diethylstilbestrol, and alpha-bungarotoxin were purchased from Wako (Tokyo, Japan). Snake venoms from Agkistrodon halys blomhoffii, Trimeresurus flavoviridis, Crotalus atrox, Naja nigricollis, and Naja naja kaouthia were purchased from LATOXAN (Valence, France). 2-Aminomethylpyridine, 1H-1,2,4-triazole, 1H-1,2,3-triazole, 3,4,4'-trichlorocarbanilide, edifenphos, dichlorvos, O-ethyl O-4-nitrophenyl phenylphosphonothioate, 2,4-dinitrophenol, N -methylaniline, 1,2-dichloro-3-nitrobenzene, 4-ethylnitrobenzene, 2-vinylpyridine, 3-amino-1H-1,2,4-triazole, N-ethyl-N-nitrosourea, 5-aza-2'- deoxycytidine, ethynyl estradiol, 3-methylcholanthrene, phenobarbital, acetaminophen, isoniazid, capsaicin, colcemid, 2.4-dinitrochlorobenzene, dexamethasone were from Sigma Chemicals (St. Louis, MO). Methoprene acid, methoprene, all-trans retinoic acid and 9-cis retinoic acid were from BIOMOL International L.P. (Plymouth Meeting, PA). Levothyroxine was from ICN (Costa Mesa, CA); 3-iodo-2-propynyl butylcarbamate was from Olin Japan Inc. (Tokyo, Japan); p-chlorophenyl-3-iodopropargylformal was from Nagase ChemteX (Osaka, Japan); 2,3,3,3-2', $3^{\prime}, 3^{\prime}, 3^{\prime}$-octachlorodipropylether was from Sankyo Chemical Industries, LTD. (Tokyo, Japan); 1,2-benzisothiazolin-3-one was from Riverson (Osaka, Japan); zinc butylxanthate was from Ouchishinko Chemical Industrial Co., Ltd. (Tokyo, Japan); and 4-amino-2,6-dichlorophenol was from Tokyo Kasei Kogyo Co. Ltd. (Tokyo, Japan).

Hierarchical Clustering. Hierarchical clustering analysis was carried out using the average linkage

## MOL \#38836

method and the "GeneSpring" software (Silicon Genetics, Inc., Redwood, CA). Pearson correlation coefficients were used to determine the degree of similarity.

## Result

Sensitivity of JFCR39 to chemicals. Sensitivity of the JFCR39 panel of cells to 130 chemicals was determined as described in Materials and Methods. Table 1 summarizes abbreviations, applications, targets, and known mechanisms of 130 chemicals and 21 anti-cancer drugs. Approximately $15 \%$ of the chemicals were assessed twice or more. Approximately $40 \%$ of the chemicals tested had little effect on the growth of cells in the JFCR39 panel. However, rest of the chemicals significantly inhibited the cell growth across the JFCR39 panel. For example, Figure 1 shows the dose response curves of the cells in the JFCR39 panel against digoxin. The concentration at which the cell growth is inhibited by $50 \%$ represents GI50. Figure 2 shows the fingerprints of four chemicals (digoxin, ouabain, snake venom from Naja nigricollis (SV-NN), and snake venom from Naja naja kaouthia (SV-NNK)), which differentially inhibited the growth of cells in the JFCR39 panel; these fingerprints were drawn based on a calculation using a set of GI50s, and clearly represented the GI50 pattern. These results were highly reproducible as the Pearson correlation coefficient of the duplicate experiments for digoxin was 0.839 ( $\mathrm{p}<0.001$ ) and that for ouabain was 0.864 ( $\mathrm{p}<0.001$ ). Interestingly, digoxin and ouabain, both of which are cardiac glycosides and inhibit Na-K ATPase, showed similar fingerprints. The fingerprints of snake venoms from the Naja naja kaouthia (SV-NNK) and Naja nigricollis (SV-NN), which belong to the elapidae, known as cobra, were also similar, but were different from the fingerprints of digoxin and ouabain. Table

2 summarizes only a portion of the GI50 values from 160 experiments involving 130 chemicals and 42 experiments involving 21 anti-cancer drugs. GI50 values from all experiments were described in the Supplemental data (Table S1). All these data were stored in a chemosensitivity database and used for further analysis.

Classification of the chemicals by hierarchical clustering. Sixty nine chemicals were selected for further analysis based on the following criteria: a) GI50 values for the test chemical can be determined for at least 10 cell lines in the JFCR39 panel, and b) the range of log GI50 for the test chemical is over 0.6 , suggesting differential growth inhibition. We analyzed the GI50 values of these 69 chemicals and 20 anti-cancer drugs by hierarchical clustering analysis (Figure 3). We roughly found 12 clusters (threshold: $r=0$, Figure 3 clusters A-L), which were further divided into 49 sub-clusters (threshold: $r=0.408$, Figure 3 clusters A1-L6).

Analysis of clusters. Most anti-cancer drugs we have tested belonged either to cluster A or cluster H, depending on their modes of action (Dan et al., 2002). The targets of the anti-cancer drugs belonging to the cluster A were related to DNA (Topo I, antimetabolite of pyridine, DNA alkylator) and the target of the anti-cancer drugs belonging to the cluster H was tubulin. We presently found that cisplatin exceptionally belonged to cluster F 2 , not cluster A , although it is known to crosslink DNA strands
(Jamieson and Lippard, 1999; Wong and Giandomenico, 1999). We were also able to precisely group the clusters into several sub-clusters having similar characteristics. For example, the cardiac glycosides digoxin and ouabain were grouped in one cluster (cluster F3). The snake venoms from the Naja naja kaouthia and Naja nigricollis, on the other hand, belonged to the cluster D2. These results are in accordance with the similar fingerprints shown in Figure 2. Interestingly, the snake venoms from the Crotalus atrox and Trimeresurus flavoviridis, species belonging to the viperidae snake family, formed another cluster (cluster D3), which was different from that of the elapidae family of snakes, Naja naja kaouthia and Naja nigricollis. 9-cis retinoic acid, 13-cis retinoic acid, and TTNPB, which are RAR agonist (Astrom et al., 1990), also formed a separate cluster (cluster D1). Similarly, agricultural chemicals paraquat, ziram, and thiram formed a single cluster (cluster F1).

## Discussion

The JFCR39 system coupled to a drug activity database is a good model for investigating the diversity of chemosensitivity in cancer cells. We have previously established panels of human cancer cell lines, JFCR39 (Yamori, 2003) and JFCR45 (Nakatsu et al., 2005), and used these panels of cells to demonstrate that they provide powerful means to predict the action mechanisms of drugs, and also used them to identify new target compounds. In this manuscript, we utilized the JFCR39 system to evaluate various chemicals (such as toxic chemicals, agricultural chemicals, and synthetic intermediates), which are not anti-cancer drugs, and classified them according to their molecular target or action mechanism. As a result, these chemicals were classified into a number of clusters. Our results also suggested that each cluster consisted of chemicals sharing a common action mechanism.

We determined the growth inhibition of cells in the JFCR39 panel by 130 chemicals and calculated their $50 \%$ growth inhibition concentration (GI50). Some of the chemicals were assessed twice or more to confirm the reproducibility of the assay. We had to exclude 61 chemicals from further analysis, as they did not inhibit the cells in the JFCR39 panel significantly. Rests of the chemicals (69 of 130, approx. $60 \%$ ) met our selection criteria and were evaluated by cluster analysis.

First, we found that the chemicals tested in duplicate formed tight clusters, showing high reproducibility. Next, we investigated the difference between these 69 test chemicals and the anti-cancer

## MOL \#38836

drugs. Sixty-nine chemicals, which are not anti-cancer drugs, formed several clusters, which were different from the anti-cancer drug clusters. These results suggest that the action mechanisms of these chemicals are different from the action mechanisms of the anti-cancer drugs. Exceptionally, we found that cisplatin did not belong to the cluster A that consisted of DNA-targeting anti-cancer drugs. We do not understand the reason at present. However, there is a possibility that cisplatin has other action mechanisms, which may have made the fingerprint of cisplatin different from those of other DNA-targeting drugs. Indeed, it is known that cisplatin forms DNA-protein cross-links (Chvalova et al., 2007; Zwelling et al., 1979).

Our analysis also identified several interesting clusters. For example, the cluster F3 consisted of cardiac glycosides digoxin and ouabain, both of which inhibit Na-K ATPase (Reuter et al., 2002). The cluster D1 consisted of 9-cis retinoic acid, 13-cis retinoic acid, and TTNPB, which are RAR agonists. These results suggest that chemicals other than the anti-cancer drugs also form clusters when they share the same action mechanisms. Interestingly, the snake venoms from the Naja naja kaouthia and Naja nigricollis, which belonged to the ellapidae family, formed one cluster (cluster D2). In contrast, the snake venoms from the Crotalus atrox and Trimeresurus flavoviridis, which belonged to the viperidae family, formed a cluster (cluster D3) that was different from the elapidae cluster. These results are reasonable because it is known that the snake venoms from different snake families not only differ in compositions but also show different levels of toxicity and have different action mechanisms.

## MOL \#38836

Agricultural chemicals paraquat, ziram and thiram were also classified into a single cluster (cluster F1). Among these agricultural chemicals, the action mechanism of ziram is not known. However, it is known that both paraquat and thiram induce oxidative stress (Cereser et al., 2001; Suntres, 2002). Therefore, based on our observation, we could suggest that ziram also act by inducing oxidative stress.

Other agricultural chemicals, methoprene (insect growth regulator) and carbaryl (chorine esterase inhibitor) formed cluster L3 although their common mechanism is unknown. Cluster D4 and D5 consist of the antibacterial agents or fungicides. Especially, IPBC and CPIP belonging cluster D4 are the iodo-type antibacterial agents.

Thus, cluster analysis of GI50 values of various chemicals, determined using the JFCR39 cell panel, suggests that the JFCR39 system could, at least partly, allow classification of chemical compounds on the basis of their action mechanisms. Our analysis also suggests that the chemicals belonging the same cluster share a common action mechanism. We are going to develop a larger library of reference chemicals with known action mechanisms, i.e. various inhibitors of biological pathways, and expand our database by integrating their GI50 measurements, which will make the cluster analysis as well as the COMPARE analysis more informative for predicting the mechanism of test chemicals.

In conclusion, to evaluate the potential of the JFCR39 system in predicting the action mechanisms of toxic chemicals, we investigated the fingerprints of 130 different types of chemical compounds including toxic chemicals, pesticides, drugs and synthetic intermediates. Using the hierarchical

## MOL \#38836

clustering analysis, we classified 69 chemicals, at least partly, on the basis of their action mechanisms.

Thus, this approach using the JFCR39 cell panel is not only useful in predicting the action mechanisms of toxic chemicals but also in evaluating their toxicity.

## MOL \#38836

## Acknowledgement

We thank Yumiko Mukai, Yumiko Nishimura, and Mariko Seki for the determination of chemosensitivity and Satoshi Kitajima for help with chemical information.

## References

Akashi T, Nishimura Y, Wakatabe R, Shiwa M and Yamori T (2007) Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. Biochem Biophys Res Commun 352(2):514-521.
Akashi T and Yamori T (2007) A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteins. Proteomics 7(14):2350-2354.
Astrom A, Pettersson U, Krust A, Chambon P and Voorhees JJ (1990) Retinoic acid and synthetic analogs differentially activate retinoic acid receptor dependent transcription. Biochem Biophys Res Commun 173(1):339-345.

Cereser C, Boget S, Parvaz P and Revol A (2001) An evaluation of thiram toxicity on cultured human skin fibroblasts. Toxicology 162(2):89-101.
Chvalova K, Brabec V and Kasparkova J (2007) Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 35(6):1812-1821.
Dan S, Shirakawa M, Mukai Y, Yoshida Y, Yamazaki K, Kawaguchi T, Matsuura M, Nakamura Y and Yamori T (2003) Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci 94(12):1074-1082.
Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y and Yamori T (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62(4):1139-1147.
Hershberger LG, Shipley EG and Meyer RK (1953) Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 83(1):175-180.
Jamieson ER and Lippard SJ (1999) Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 99(9):2467-2498.
Kanno J, Kato H, Iwata T and Inoue T (2002) Phytoestrogen-low diet for endocrine disruptor studies. $J$ Agric Food Chem 50(13):3883-3885.

Naasani I, Seimiya H, Yamori T and Tsuruo T (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59(16):4004-4011.
Nakamura H, Dan S, Akashi T, Unno M and Yamori T (2007) Absolute Quantification of Four Isoforms of the Class I Phosphoinositide-3-kinase Catalytic Subunit by Real-Time RT-PCR. Biol Pharm Bull 30(6):1181-1184.
Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y and Yamori T (2005) Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer

Ther 4(3):399-412.
Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang YH, Motoji T, Ohno R and Nakamura Y (2002) Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 1(12):1035-1042.
Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14):1088-1092.

Reuter H, Henderson SA, Han T, Ross RS, Goldhaber JI and Philipson KD (2002) The Na+-Ca2+ exchanger is essential for the action of cardiac glycosides. Circ Res 90(3):305-308.
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24(3):236-244.
Suntres ZE (2002) Role of antioxidants in paraquat toxicity. Toxicology 180(1):65-77.
Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD and Chiausa AJ (1992) Neural computing in cancer drug development: predicting mechanism of action. Science 258(5081):447-451.
Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr., Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275(5298):343-349.

Wong E and Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99(9):2451-2466.
Yamori T (2003) Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52 Suppl 1:S74-79.
Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T and Tsuruo T (1999) Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59(16):4042-4049.
Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K and Nakamura Y (2002) Genome-wide cDNA microarray screening to

## MOL \#38836

correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62(2):518-527.
Zwelling LA, Anderson T and Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cisand trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39(1):365-369.

## Footnotes

## a) Unnumbered footnote

N. N. and T. N. equally contributed to this study.

This work was partly supported by Grants-in-Aid for Scientific Research (B) from Japan Society for the Promotion of Science to T. Y. (17390032); MHLW grant-in-aids Grant-in-Aid H15-kagaku-002, H16-kagaku-003 to T.Y. and J. K.; Grants-in-Aid of the Priority Area "Cancer" from the Ministry of Education, Culture, Sports, Science and Technology of Japan to T. Y. (18015049); and Grant from National Institute of Biomedical Innovation, Japan, to T. Y. (05-13)

## b) The name and full address to receive reprint requests

Takao Yamori

Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer

Research, 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, Japan.

Phone: 81-3-3520-0111

Fax: 81-3-3570-0484

E-mail: yamori@jfcr.or.jp

## Legends for figures

Figure 1. Dose response curves of digoxin against growth of JFCR-39 cells.

X -axis is the concentration of digoxin and Y-axis is the \% growth. The GI50 represents the concentration required to inhibit cell growth by $50 \%$ compared with untreated controls.

Figure 2. Fingerprints of digoxin, ouabain, SV-NN, and SV-NNK.

Fingerprint shows the differential growth inhibition pattern of the cells in the JFCR-39 panel against the test chemical. X - axis represents relative value of GI50; (-1) x (log GI50- MG-MID); MG-MID is the mean value of the $\log$ GI50. Zero means the mean GI50 and one means the GI50 value is ten-fold more sensitive than the mean GI50. Exp-ID and JCI numbers are the ID for the experiment and ID for the chemical, respectively, in our database.

Figure 3. Hierarchical clustering of 69 test chemicals and 20 anti-cancer drugs based on their GI50 values.

Hierarchical clustering method was an "average linkage method" using the Pearson correlation as distance. We classified the chemicals into two kinds of clusters; their threshold values were $\mathrm{r}=0$ and $\mathrm{r}=0.408$ ( $\mathrm{p}<0.01$ ), respectively. Gradient color indicates relative level (log transformed) of GI50. Red,

## MOL \#38836

more sensitive than the mean GI50 (2.0); yellow, mean GI50 (0.0); and green, less sensitive than the mean GI50 (-2.0). On the color scale, red represents the GI50 value that is 100 -fold higher the mean GI50.

MOL \#38836

Table 1. List of chemicals tested. Chemical names, abbreviations, and applications/targets/mechanisms of the test compounds are summarized.

| JCl No | name | abbreviation | application / target / mechanism |
| :---: | :---: | :---: | :---: |
| -691 | Trioctyltin | TOT | Organotin |
| -690 | Triphenyltin | TPT | Organotin |
| -689 | Dibutyltin |  | Organotin |
| -688 | AM-580 |  | RARalpha |
| -687 | TTNPB |  | RAR |
| -686 | 13-cis Retinoic acid | 13 -cis | RAR |
| -607 | Methoprene |  | agricultural chemical |
| -606 | Methoprene acid |  | RXR |
| -605 | 5-aza-2'- deoxycytidine | 5-AzaC | methylation |
| -604 | Carbaryl |  | agricultural chemical |
| -603 | Acephate |  | agricultural chemical |
| -602 | Sodium Arsenite |  | agricultural chemical |
| -601 | Testosterone propionate | TP | testosterone |
| -600 | Ethynyl estradiol | EE | estrogenic |
| -599 | Thiram |  | agricultural chemical |
| -598 | Dimethylformamide | DMF | solvent |
| -568 | alpha-Bungarotoxin | alphaBuTX | neurotoxin |
| -567 | Snake Venom from Trimeresurus flavoviridis | SV-TF | snake venom |
| -566 | Snake Venom from Crotalus atrox | SV-CA | snake venom |
| -565 | Snake Venom from Agkistrodon halys blomhoffii | SV-AHB | snake venom |
| -564 | Dexamethasone | DEX | steroid |
| -563 | 3-methylcholanthrene | 3-MC | teratogenicity / carcinogenicity |
| -562 | N -ethyl-N-nitrosourea | ENU | teratogenicity / carcinogenicity |
| -561 | Diethylnitrosamine | DEN | teratogenicity / carcinogenicity |
| -560 | All trans retinoic acid | ATRA | RAR + RXR |
| -559 | 9-cis retinoic acid | 9-cis | RAR |
| -558 | Levothyroxine | T4 | thyroid hormone |
| -557 | 3-Amino-1H-1,2,4-triazole | 3AST | agricultural chemical |
| -555 | 2-Vinylpyridine | 2VP | synthetic intermediate |
| -553 | Phenobarbital | PB | antiepileptic |
| -552 | Acetaminophen | APAP | analgetic |
| -551 | Isoniazid |  | phthisic |
| -549 | 4-Ethylnitrobenzene | 4ENB | synthetic intermediate |
| -548 | 1,2-Dichloro-3-nitrobenzene | 1,2DC3NB | pigment / synthetic intermediate |
| -546 | N -Methylaniline | NMA | synthetic intermediate |
| -545 | 2-Aminomethylpyridine | 2AMP | synthetic intermediate |
| -544 | 1H-1,2,4-Triazole |  | synthetic intermediate |
| -543 | 1H-1,2,3-Triazole |  | synthetic intermediate |
| -542 | 4-amino-2,6-dichlorophenol | 4A2,6DCP | synthetic intermediate |
| -541 | 2,4-dinitrophenol | 2,4 DNP | agricultural chemical |
| -513 | Capsaicin |  | food constituent |
| -485 | 2-Methoxyestradiol |  | estrogenic |
| -466 | Colcemid |  | spindle inhibitor |
| -465 | 2,4-Dinitrochlorobenzene | 2,4DCB | pigment / mutagenesis |
| -464 | Troglltazone |  | diabetic |
| -463 | Clofibrate |  | antilipemic |
| -459 | Bis(2-ethylhexyl)Phthalate | DEHP | plasticizer |
| -458 | Thiourea |  | agricultural chemical |
| -447 | Cacodylic acid Amitrole |  | agricultural chemical agricultural chemical |

Table 1. List of chemicals tested. (Cont'd)

| JCI No | name | abbreviation | application / target / mechanism |
| :---: | :---: | :---: | :---: |
| -445 | 4-Octylphenol | OP | reproductive effector |
| -444 | 2,6-Dimethylaniline | 2,6-Xylidene | natural product |
| -443 | 1,2-Dibromo-3-chloropropane | DBCP | agricultural chemical |
| -442 | 1,1-Dimethylhydrazine | 1,1DMH | reproductive effector |
| -441 | Sulfanylamide |  | agricultural chemical |
| -440 | Streptozotocin |  | agricultural chemical |
| -439 | Spironolactone |  | aldosterone antagonist |
| -438 | para-Aminoazobenzene | pAAB | pigment / mutagenicity / carcinogenicity |
| -437 | para-Cresidine |  | pigment / carcinogenicity |
| -436 | Neostigmin bromide |  | parasympathomimetics |
| -435 | para-Dichlorobenzene | pDCB | pigment / agricultural chemical |
| -434 | Phenytoin |  | antiepileptic |
| -433 | ortho-Toluidine | oToluidine | pigment |
| -432 | Imipramine |  | antidepressant |
| -431 | Cobalt chloride |  | teratogenicity / mutagenicity |
| -428 | Atrazine |  | agricultural chemical |
| -427 | Propylthiouracil |  | teratogenicity / carcinogenicity |
| -426 | Thalidomide(L+D) |  | teratogenicity |
| -425 | Carbon tetrachloride | CCl 4 | teratogenicity / carcinogenicity |
| -424 | Hydroquinone |  | oxidative stress |
| -423 | Monocrotaline |  | mutagenicity / carcinogenicity |
| -422 | Vinyl chloride |  | carcinogenicity |
| -421 | Tributyltin chloride | TBT | ship bottom paint / organotin |
| -420 | Valproic acid |  | antiepileptic |
| -419 | Benzene |  | carcinogenicity |
| -418 | Acrylamide |  | neurotoxin / carcinogenicity |
| -417 | Hexachlorobenzene | BHC | agricultural chemical / carcinogenicity |
| -346 | 2-deoxy-glucose | 2-DG | glycolytic pathway / glycosylation inhibitor |
| -325 | Pentachlorophenol | PCP | agricultural chemical / teratogenicity / carcinogenicity |
| -324 | Aniline |  | oxidative stress / methemoglobinemia / carcinogenicity |
| -323 | Triazine |  | agricultural chemical |
| -322 | Edifenphos | EDDP | agricultural chemical / antibiotics / choline esterase |
| -321 | gamma-1,2,3,4,5,6-■Hexachlorocyclohexane | gamma-BHC | agricultural chemical / carcinogenicity |
| -320 | Dichlorvos | DDVP | agricultural chemical / teratogenicity / carcinogenicity |
| -319 | O-ethyl O-4-nitrophenyl phenylphosphonothioate | EPN | agricultural chemical |
| -318 | Cadmium chloride | CdCl2 | teratogenicity / carcinogenicity |
| -317 | phenylmercury acetate | PMA | fungicides / mutagenicity |
| -316 | Mercaptoacetic Acid |  | synthetic intermediate |
| -315 | 1,3-diphenylguanidine | DPG | vulcanizing agent |
| -314 | 3,4,4'-Trichlorocarbanilide | TCC | cosmetics / antibacterial agent |
| -313 | 3-lodo-2-propynyl butylcarbamate | IPBC | antibacterial agent |
| -311 | 2,3,3,3-2',3',3',3'-■octachlorodipropylether | S-421 | agricultural chemical / antibacterial agent |
| -310 | 1,2-Benzisothiazolin-3-one | BIT | antibacterial agent |
| -309 | Isobornylthiocyanoacetate | IBTA | antibacterial agent |
| -308 | p-Chlorophenyl-3-iodopropargylformal | CPIP | antibacterial agent |
| -307 | Zinc butylxanthate | ZBX | vulcanizing agent |
| -306 | Polypropylene glycol | PG | synthetic intermediate |
| -305 | 10,10'-Oxy-bis(phenoxyarsine) | OBPA | antibacterial agent |
| -296 | Snake Venom $\ddagger$ from Naja naja kaouthia | SV-NNK | snake venom |
| -295 | Snake Venom from Naja nigricollis | SV-NN | snake venom |

Table 1.List of chemicals tested. (Cont'd)

| JCl No | name | abbreviation | application / target / mechanism |
| :---: | :---: | :---: | :---: |
| -294 | 2,5-di(tert-butyl)-1,4-hydroquinone | DTBHQ | oxidative stress |
| -293 | Ibotenic Acid |  | mushroom toxin / neurotoxin |
| -292 | N-methy-4-phenyl-1,2,3,6-tetrahydropyridine | MPTP | neurotoxin |
| -289 | Tetrodotoxine |  | natural product / $\mathrm{Na}+$ channel inhibitor |
| -288 | ICI 182,780 |  | estrogen antagonist |
| -275 | Benzophenone |  | agricultural chemical |
| -274 | 1,2-dibromo-3-chloropropane | DBCP | antibacterial agent / insecticide / carcinogenicity |
| -273 | Zineb |  | agricultural chemical |
| -272 | Dieldrin |  | insecticide |
| -271 | Hexachlorobenzene | HCB | antibacterial agent / carcinogenicity |
| -270 | Ziram |  | antibacterial agent / vulcanizing agent |
| -269 | chlordane |  | insecticide / carcinogenicity |
| -268 | 4,4'-Dichlorodiphenyltrichloroethane | p,p'-DDT | insecticide / carcinogenicity / teratogenicity |
| -267 | Bisphenol A | BPA | estrogenic |
| -266 | 17-beta-estradiol | E2 | estrogenic |
| -265 | Diethylstilbestrol | DES | estrogenic |
| -261 | Paraquat |  | agricultural chemical / oxidative stress |
| -247 | Ouabain |  | cardiac glycosides |
| -245 | Okadaic acid |  | natural product / PP1, PP2A inhibitor |
| -242 | Antimycin A1 |  | agricultural chemical |
| -232 | Digoxin |  | cardiac glycosides |
| -201 | OH-Flutamide |  | Flutamide derivative / androgen antagonist |
| -200 | Flutamide |  | anti-cancer drugs / androgen antagonist |
| -185 | 30\%H2O2 |  | oxidative stress |
| -182 | N -Acetyl-L-cysteine | NAC | super oxyside scavenger |
| -181 | L-Ascorbic acid |  | food constituent |
| -179 | Dopamine |  | neurotransmitter |
| -177 | Caffeine |  | food constituent |
| -168 | Cycloheximide |  | protein synthesis inhibitor |
| -144 | 4-Hydroxy phenylretinamide | 4-HPR | RAR |
| -137 | Indomethacin |  | cox inhibitor |
| -99 | SN-38 |  | Irinotecan derivative / Topo I |
| -96 | Toremifene |  | anti-cancer drugs / estrogen antagonist |
| -95 | Tamoxifen |  | anti-cancer drugs / estrogen antagonist |
| -63 | Cychlospolin A |  | anti-cancer drugs / helper T cell |
| -46 | HCFU |  | anti-cancer drugs / antimetabolite(pyrimidine) |
| -36 | Taxotere |  | anti-cancer drugs / tubulin |
| -35 | Taxol |  | anti-cancer drugs / tubulin |
| -34 | Colchicine |  | antipodagric / tubulin |
| -33 | Cisplatin |  | anti-cancer drugs / DNA cross linker |
| -32 | Carboplatin |  | anti-cancer drugs / DNA cross linker |
| -31 | Irinotecan |  | anti-cancer drugs / Topo I |
| -30 | Camptothecin | CPT | anti-cancer drugs / Topo I |
| -24 | Methotrexate |  | anti-cancer drugs / DHFR |
| -19 | Vincristine |  | anti-cancer drugs / tubulin |
| -18 | Vinblastine |  | anti-cancer drugs / tubulin |
| -16 | Mitomycin-C | MMC | anti-cancer drugs / DNA alkylator |
| -9 | Tegafur |  | anti-cancer drugs / antimetabolite(pyrimidine) |
| -8 | 5-Fluorouracil | 5-FU | anti-cancer drugs / antimetabolite(pyrimidine) |
| -5 | Cytarabine |  | anti-cancer drugs / antimetabolite(pyrimidine) |
| -4 | Nitrogen mustard |  | anti-cancer drugs / DNA alkylator |

## MOL \#38836

Table 2. $\mathrm{bg}_{10} \mathrm{G}$ 50 values of chem icals for each cell line in the JFCR-39 panel.
$\mathrm{H} \dot{\mathrm{r}}$ conc m eans the highest concentration of the test chem icalused. When the grow th inhibition was over $50 \%$ at the $\mathrm{Hi} \mathrm{Conc}, \mathrm{G} 50$ was assigned the $\mathrm{H} \dot{\mathrm{F}} \mathrm{C}$ onc value.

| Exp-ID | S3416 | S3415 | S3413 | S3245 | S3117 | S3414 | S3118 | S3246 | S3125 | S3124 | S3123 | S1636 | S1635 | S1634 | S1718 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| JCINo | -687 | -686 | -559 | -559 | -559 | -560 | -560 | -560 | -567 | -566 | -565 | -296 | -295 | -294 | -294 |
|  | $\stackrel{\infty}{0}$ | $\begin{aligned} & \mathscr{O} \\ & \dot{\sim} \\ & \end{aligned}$ | $\begin{aligned} & \% \\ & \stackrel{\omega}{6} \end{aligned}$ | $\begin{aligned} & \% \\ & \hline 10 \\ & \hline 1 \end{aligned}$ | $\begin{aligned} & \text { ๗ } \\ & \stackrel{1}{2} \end{aligned}$ |  |  |  | $\stackrel{\stackrel{\mu}{1}}{\stackrel{\rightharpoonup}{\prime}}$ | $\begin{aligned} & \mathbb{1} \\ & \vdots \\ & \vdots \end{aligned}$ | $\begin{aligned} & \text { м } \\ & \frac{1}{\top} \\ & \underset{1}{1} \end{aligned}$ | $\underset{\substack{\sum}}{\sum_{i}^{\prime}}$ | $\underset{\substack{1 \\ \vdots}}{\substack{1}}$ | $\begin{aligned} & \stackrel{\text { O}}{1} \\ & \stackrel{9}{\circ} \end{aligned}$ | ¢ <br> ¢ <br> ¢ <br> - |
| Hi-Conc. | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 |
| HBC-4 | -4.76 | -4.00 | -4.53 | -4.40 | -4.43 | -4.42 | -4.41 | -4.41 | -5.87 | -5.80 | -5.66 | -7.25 | -7.31 | -4.72 | -4.80 |
| BSY-1 | -4.78 | -4.16 | -4.60 | -4.73 | -4.73 | -4.69 | -4.70 | -4.81 | -6.31 | -6.06 | -5.76 | -6.93 | -7.34 | -5.07 | -4.93 |
| HBC-5 | -4.80 | -4.41 | -4.56 | -4.57 | -4.61 | -4.61 | -4.47 | -4.51 | -6.98 | -6.45 | -5.73 | -7.64 | -7.72 | -4.89 | -4.78 |
| MCF-7 | -4.73 | -4.35 | -4.40 | -4.39 | -4.48 | -4.48 | -4.54 | -4.66 | -5.87 | -5.78 | -5.68 | -6.77 | -7.08 | -5.29 | -5.25 |
| $\begin{gathered} \text { MDA- } \\ \text { MB-231 } \end{gathered}$ | -4.75 | -4.21 | -4.70 | -4.55 | -4.69 | -4.63 | -4.53 | -4.65 | -5.90 | -5.86 | -5.84 | -6.84 | -7.39 | -5.52 | -5.30 |
| U251 | -4.77 | -4.14 | -4.61 | -4.51 | -4.61 | -4.57 | -4.45 | -4.63 | -6.45 | -5.76 | -5.70 | -6.85 | -7.44 | -4.96 | -5.11 |
| SF-268 | -4.75 | -4.00 | -4.24 | -4.55 | -4.40 | -4.47 | -4.48 | -4.76 | -5.90 | -5.79 | -5.70 | -7.53 | -7.67 | -4.77 | -4.81 |
| SF-295 | -4.80 | -4.29 | -4.54 | -4.66 | -4.60 | -4.59 | -4.48 | -4.57 | -6.19 | -5.80 | -5.74 | -6.89 | -6.97 | -4.87 | -4.97 |
| SF-539 | -4.95 | -4.35 | -4.75 | -4.80 | -4.79 | -4.80 | -4.71 | -4.76 | -6.39 | -5.96 | -5.81 | -7.79 | -7.75 | -4.79 | -4.86 |
| SNB-75 | -5.31 | -5.28 | -5.13 | -5.19 |  | -4.71 | -4.69 | -4.87 | -6.41 | -6.33 | -5.93 | -7.60 | -7.70 | -4.67 | -4.80 |
| SNB-78 | -4.77 | -4.25 | -4.69 | -4.78 | -4.86 | -4.49 | -4.70 | -4.68 | -6.19 | -6.00 | -5.95 | -6.97 | -7.53 | -4.75 | -4.75 |
| $\begin{aligned} & \text { HCC } \\ & 2998 \end{aligned}$ | -4.68 | -4.00 | -4.48 | -4.61 | -4.62 | -4.55 | -4.62 | -4.76 | -5.91 | -5.75 | -5.67 | -6.47 | -6.77 | -4.82 | -4.75 |
| KM-12 | -4.70 | -4.00 | -4.46 | -4.51 | -4.48 | -4.51 | -4.47 | -4.58 | -5.93 | -5.80 | -5.65 | -6.77 | -6.87 | -4.74 | -4.77 |
| HT-29 | -4.73 | -4.00 | -4.47 | -4.53 | -4.50 | -4.60 | -4.52 | -4.56 | -5.90 | -5.80 | -5.56 | -5.89 | -6.78 | -4.80 | -4.89 |
| $\begin{gathered} \text { HCT- } \\ 15 \end{gathered}$ | -4.72 | -4.25 | -4.45 | -4.49 | -4.48 | -4.52 | -4.57 | -4.53 | -5.88 | -5.76 | -5.57 | -6.73 | -6.82 | -4.72 | -4.77 |
| $\begin{gathered} \text { HCT- } \\ 116 \end{gathered}$ | -4.77 | -4.07 | -4.67 | -4.59 | -4.67 | -4.71 | -4.61 | -4.64 | -6.46 | -6.10 | -5.77 | -6.58 | -6.82 | -4.98 | -5.13 |
| $\begin{aligned} & \mathrm{NCl}- \\ & \mathrm{H} 23 \end{aligned}$ | -4.74 | -4.00 | -4.47 | -4.60 | -4.59 | -4.61 | -4.55 | -4.63 | -6.11 | -5.75 | -5.72 | -6.86 | -7.42 | -4.76 | -4.90 |
| $\begin{aligned} & \text { NCI- } \\ & \mathrm{H} 226 \end{aligned}$ | -4.72 | -4.00 | -4.61 | -4.68 | -4.78 | -4.80 | -4.54 | -5.48 | -5.95 | -5.81 | -5.76 | -6.73 | -6.78 | -4.89 | -4.91 |
| $\begin{aligned} & \mathrm{NCI}- \\ & \mathrm{H} 522 \end{aligned}$ | -4.72 | -4.45 | -4.68 | -4.82 | -4.77 | -4.71 | -4.71 | -4.68 | -6.45 | -5.99 | -5.78 | -7.62 | -7.46 | -5.37 | -5.37 |
| $\begin{aligned} & \mathrm{NCl}- \\ & \mathrm{H} 460 \end{aligned}$ | -4.70 | -4.00 | -4.55 | -4.63 | -4.58 | -4.68 | -4.55 | -4.49 | -5.96 | -5.82 | -5.72 | -7.44 | -7.42 | -4.84 | -4.84 |
| A549 | -4.79 | -4.00 | -4.72 | -4.77 | -4.78 | -4.70 | -4.62 | -4.53 | -5.91 | -5.79 | -5.71 | -6.80 | -6.83 | -4.83 | -4.87 |
| DMS273 | -4.57 | -4.21 | -4.50 | -4.62 | -4.55 | -4.57 | -4.51 | -4.49 | -6.20 | -5.81 | -5.72 | -7.43 | -7.44 | -4.91 | -4.98 |
| DMS114 | -4.77 | -4.16 | -4.33 | -4.62 | -4.49 | -4.51 | -4.53 | -4.61 | -6.66 | -6.33 | -5.77 | -6.83 | -6.88 | -5.12 | -5.21 |
| $\begin{aligned} & \text { LOX- } \\ & \text { IMVI } \end{aligned}$ | -4.77 | -4.69 | -4.68 | -4.66 | -4.70 | -4.77 | -4.74 | -4.74 | -6.75 | -6.59 | -5.76 | -6.86 | -6.94 | -5.05 | -5.15 |
| $\begin{gathered} \text { OVCAR } \\ -3 \end{gathered}$ | -4.77 | -4.38 | -4.56 | -4.67 | -4.72 | -4.64 | -4.62 | -4.71 | -6.61 | -6.13 | -5.89 | -6.77 | -6.79 | -4.89 | -4.86 |
| $\begin{gathered} \text { OVCAR } \\ -4 \end{gathered}$ | -4.72 | -4.05 | -4.63 | -4.64 | -4.64 | -4.58 | -4.39 | -4.54 | -6.73 | -6.23 | -5.80 | -6.82 | -6.90 | -5.13 | -4.90 |
| $\begin{gathered} \text { OVCAR } \\ -5 \end{gathered}$ | -4.75 | -4.00 | -4.33 | -4.39 | -4.42 | -4.44 | -4.34 | -4.44 | -5.92 | -5.74 | -5.67 | -6.46 | -6.71 | -5.22 | -5.26 |
| $\begin{aligned} & \text { OVCAR } \\ & -8 \end{aligned}$ | -4.75 | -4.23 | -4.50 | -4.53 | -4.59 | -4.66 | -4.67 | -4.70 | -5.95 | -5.77 | -5.69 | -6.82 | -6.84 | -4.64 | -4.70 |
| SK-OV-3 | -4.79 | -4.00 | -4.49 | -4.51 | -4.81 | -4.52 | -4.54 | -4.50 | -5.76 | -5.64 | -4.91 | -6.75 | -6.76 | -4.64 | -4.74 |
| $\begin{aligned} & \text { RXF- } \\ & \text { 631L } \end{aligned}$ | -4.77 | -4.00 | -4.54 | -4.58 | -4.60 | -4.72 | -4.63 | -4.61 | -5.91 | -5.80 | -5.59 | -7.13 | -7.46 | -4.81 | -4.84 |
| ACHN | -4.73 | -4.00 | -4.56 | -4.66 | -4.56 | -4.50 | -4.40 | -4.76 | -5.90 | -5.79 | -5.73 | -6.74 | -6.80 | -4.71 | -4.83 |
| St-4 | -4.74 | -4.00 | -4.42 | -4.54 | -4.65 | -4.53 | -4.49 | -4.57 | -5.91 | -5.81 | -5.76 | -7.65 | -7.70 | -4.68 | -4.75 |
| MKN1 | -4.75 | -4.33 | -4.56 | -4.63 | -4.62 | -4.56 | -4.45 | -4.48 | -6.15 | -5.81 | -5.78 | -7.67 | -7.68 | -4.59 | -4.81 |
| MKN7 | -4.78 | -4.40 | -4.68 | -4.59 | -4.70 | -4.73 | -4.56 | -4.65 | -6.29 | -5.85 | -5.76 | -6.70 | -6.90 | -4.79 | -4.84 |
| MKN28 | -4.71 | -4.28 | -4.56 | -4.59 | -4.59 | -4.65 | -4.56 | -4.60 | -6.10 | -5.93 | -5.68 | -6.51 | -6.81 | -4.72 | -4.89 |
| MKN45 | -4.72 | -4.00 | -4.51 | -4.41 | -4.46 | -4.73 | -4.41 | -4.43 | -6.06 | -5.90 | -5.69 | -6.71 | -6.82 | -4.71 | -4.87 |
| MKN74 | -4.74 | -4.40 | -4.61 | -4.63 | -4.61 | -4.73 | -4.68 | -4.67 | -5.97 | -5.92 | -5.61 | -6.92 | -7.00 | -5.10 | -5.42 |
| DU-145 | -4.68 | -4.00 | -4.25 | -4.78 | -4.41 | -4.42 | -4.44 | -4.54 | -6.08 | -5.82 | -5.75 | -7.43 | -7.55 | -4.59 | -5.02 |
| PC-3 | -4.74 | -4.00 | -4.58 | -4.65 | -4.48 | -4.74 | -4.39 | -4.51 | -5.83 | -5.77 | -5.61 | -6.67 | -6.69 | -4.89 | -4.74 |

Table 2. $\log _{10} G$ 50 values of chem icals for each cell line in the JFC R-39 panel. (Cont'd)

| Exp-ID | S3243 | S3244 | S1534 | S3237 | S3238 | S1525 | S3236 | S1928 | S1421 | S1705 | S1327 | S1413 | S1413 | S3408 | S3409 | S2421 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| JCI No | -599 | -599 | -270 | -270 | -270 | -261 | -261 | -261 | -247 | -247 | -232 | -232 | -232 | -421 | -421 | -421 |
|  |  |  | $\begin{aligned} & \underset{N}{\mathbb{N}} \\ & \stackrel{\rightharpoonup}{N} \end{aligned}$ | $\begin{aligned} & \frac{E}{N / \frac{N}{N}} \end{aligned}$ | $\begin{aligned} & \underset{N}{\bar{N}} \\ & \stackrel{N}{N} \end{aligned}$ |  |  |  |  |  | $\begin{aligned} & . \frac{ㄷ ㅡ ~}{x} \\ & .0 \\ & \hline \text { O} \end{aligned}$ | $\begin{aligned} & \text { 듬 } \\ & \text {.on } \end{aligned}$ |  | $\stackrel{\leftarrow}{\bullet}$ | $\stackrel{\leftarrow}{\perp}$ | $\stackrel{\leftarrow}{\bullet}$ |
| Hi-Conc. | -4 | -4 | -4 | -4 | -4 | -4 | -3 | -4 | -4 | -6 | -4 | -4 | -4 | -4 | -4 | -4 |
| HBC-4 | -4.71 | -4.79 | -5.80 | -5.73 | -5.70 | -4.00 | -3.61 | -4.00 | -7.54 | -7.28 | -6.57 | -6.96 | -6.96 | -6.79 | -6.77 | -6.72 |
| BSY-1 | -6.97 | -7.12 | -6.85 | -6.76 | -6.60 | -4.00 | -4.45 | -4.51 | -8.00 | -7.76 | -7.58 | -7.68 | -7.68 | -7.03 | -7.01 | -6.83 |
| HBC-5 | -7.41 | -7.66 | -7.18 | -7.47 | -7.47 | -4.68 | -4.70 |  | -7.76 | -7.51 | -7.15 | -7.44 | -7.44 | -6.76 | -6.88 | -6.83 |
| MCF-7 | -4.77 | -4.80 | -6.00 | -5.84 | -5.83 | -4.06 | -3.72 | -4.00 | -7.64 | -7.51 | -7.29 | -7.39 | -7.39 | -6.86 | -6.84 | -6.79 |
| $\begin{aligned} & \text { MDA- } \\ & \text { MB-231 } \end{aligned}$ | -4.66 | -4.68 | -5.64 | -5.75 | -5.63 | -4.00 | -3.57 | -4.00 | -7.40 | -6.81 | -6.41 | -6.72 | -6.72 | -6.83 | -6.81 | -6.70 |
| U251 | -4.75 | -4.78 | -5.71 | -5.79 | -5.82 | -4.00 | -3.69 | -4.00 | -7.75 | -7.16 | -7.01 | -7.40 | -7.40 | -6.79 | -6.77 | -6.72 |
| SF-268 | -4.86 | -4.96 | -5.74 | -5.83 | -7.01 | -4.00 | -4.08 | -4.00 | -8.00 | -7.77 | -7.42 | -7.70 | -7.70 | -6.84 | -6.85 | -6.71 |
| SF-295 | -4.77 | -4.89 | -5.71 | -5.70 | -5.79 | -4.47 | -4.37 | -4.20 | -8.00 | -7.64 | -7.42 | -7.55 | -7.55 | -6.75 | -6.73 | -6.76 |
| SF-539 | -4.75 | -4.88 | -5.73 | -5.75 | -5.77 | -4.00 | -4.03 | -4.00 | -8.00 | -7.70 | -7.46 | -7.63 | -7.63 | -6.77 | -6.72 | -6.67 |
| SNB-75 | -4.71 | -4.96 | -5.79 | -5.92 | -5.80 | -4.00 | -3.94 | -4.00 | -7.70 | -7.45 | -6.86 | -7.40 | -7.40 | -6.99 | -6.95 | -7.05 |
| SNB-78 | -4.70 | -4.78 | -5.69 | -5.64 | -5.69 | -4.00 | -3.78 | -4.00 | -7.98 | -7.64 | -7.45 | -7.60 | -7.60 | -6.72 | -6.79 | -6.70 |
| $\begin{aligned} & \text { HCC } \\ & 2998 \end{aligned}$ | -4.82 | -4.69 | -5.76 | -5.79 | -5.81 | -4.00 | -3.70 | -4.00 | -7.64 | -6.77 | -6.68 | -7.25 | -7.25 | -6.77 | -6.79 | -6.72 |
| KM-12 | -4.80 | -4.80 | -5.43 | -5.74 | -5.73 | -4.00 | -3.58 | -4.00 | -7.67 | -7.12 | -6.69 | -7.34 | -7.34 | -7.00 | -6.98 | -6.74 |
| HT-29 | -4.68 | -4.85 | -5.75 | -5.77 | -5.76 | -4.10 | -4.03 | -4.07 | -7.75 | -7.31 | -7.20 | -7.34 | -7.34 | -6.89 | -6.84 | -6.66 |
| $\begin{gathered} \text { HCT- } \\ 15 \end{gathered}$ | -4.68 | -4.75 | -5.70 | -5.72 | -5.83 | -4.00 | -3.64 | -4.00 | -7.74 | -7.63 | -6.92 | -7.54 | -7.54 | -6.88 | -6.84 | -6.70 |
| $\begin{gathered} \text { HCT- } \\ 116 \end{gathered}$ | -4.72 | -4.72 | -5.74 | -5.68 | -5.77 | -4.00 | -3.60 | -4.00 | -8.00 | -7.57 | -7.47 | -7.62 | -7.62 | -6.90 | -6.85 | -6.74 |
| $\begin{aligned} & \mathrm{NCl} \\ & \mathrm{H} 23 \end{aligned}$ | -4.69 | -4.78 | -5.96 | -5.85 | -5.84 | -4.19 | -4.18 | -4.00 | -8.00 | -7.67 | -7.50 | -7.84 | -7.84 | -6.90 | -6.85 | -6.76 |
| $\begin{aligned} & \mathrm{NCI} \\ & \mathrm{H} 226 \end{aligned}$ | -6.33 | -6.74 | -5.63 | -5.96 | -6.12 | -4.41 | -4.41 | -4.00 | -8.00 | -7.37 | -6.93 | -7.61 | -7.61 | -6.99 | -6.91 | -6.74 |
| $\begin{aligned} & \mathrm{NCI}- \\ & \mathrm{H} 522 \end{aligned}$ | -7.49 | -7.50 | -7.44 | -7.66 | -8.00 | -4.49 | -4.71 | -4.59 | -8.00 | -7.64 | -7.59 | -7.91 | -7.91 | -6.83 | -6.80 | -6.25 |
| $\begin{aligned} & \mathrm{NCI} \\ & \mathrm{H} 460 \end{aligned}$ | -6.14 | -6.16 | -6.30 | -6.10 | -6.15 | -4.30 | -4.45 | -4.37 | -8.00 | -7.74 | -7.60 | -7.77 | -7.77 | -6.98 | -6.98 | -6.56 |
| A549 | -4.84 | -4.82 | -5.97 | -5.91 | -5.91 | -4.49 | -4.49 | -4.41 | -8.00 | -7.80 | -7.66 | -7.91 | -7.91 | -6.82 | -6.87 | -6.73 |
| DMS273 | -6.64 | -6.58 | -6.43 | -6.84 | -6.82 | -4.25 | -4.43 | -4.30 | -8.00 | -7.71 | -7.48 | -7.72 | -7.72 | -6.74 | -6.75 | -6.70 |
| DMS114 | -7.18 | -7.39 | -7.37 | -7.38 | -7.43 | -4.50 | -4.63 | -4.27 | -8.00 | -7.84 | -7.73 | -8.00 | -8.00 | -7.11 | -7.12 | -7.02 |
| LOX- <br> IMVI | -4.68 | -4.71 | -5.66 | -5.71 | -5.70 | -4.00 | -3.51 | -4.00 | -7.80 | -7.80 | -7.39 | -7.46 | -7.46 | -6.93 | -6.94 | -6.76 |
| $\begin{gathered} \text { OVCAR } \\ -3 \end{gathered}$ | -4.86 | -6.25 | -6.07 | -6.35 | -6.32 | -4.00 | -4.46 | -4.28 | -8.00 | -7.66 | -7.64 | -7.59 | -7.59 | -6.80 | -6.82 | -6.74 |
| $\begin{gathered} \text { OVCAR } \\ -4 \end{gathered}$ | -4.77 | -6.67 | -5.90 | -5.91 | -5.87 | -4.00 | -4.21 | -4.48 | -8.00 | -7.71 | -7.71 | -7.72 | -7.72 | -6.91 | -7.20 | -6.80 |
| $\begin{gathered} \text { OVCAR } \\ -5 \end{gathered}$ | -4.90 | -6.00 | -6.11 | -6.91 | -6.74 | -4.00 | -3.98 | -4.00 | -7.89 | -7.62 | -7.12 | -7.42 | -7.42 | -6.90 | -6.93 | -6.75 |
| $\begin{aligned} & \text { OVCAR } \\ & -8 \end{aligned}$ | -4.62 | -4.74 | -5.59 | -5.68 | -5.67 | -4.00 | -3.84 | -4.00 | -7.85 | -7.44 | -6.97 | -7.29 | -7.29 | -6.73 | -6.67 | -6.57 |
| SK-OV-3 | -4.39 | -4.38 | -4.92 | -5.49 | -5.53 | -4.00 | -3.39 | -4.00 | -7.74 | -7.67 | -7.18 | -7.38 | -7.38 | -6.80 | -6.77 | -6.68 |
| $\begin{aligned} & \text { RXF- } \\ & \text { 631L } \end{aligned}$ | -4.75 | -4.65 | -5.57 | -5.63 | -5.60 | -4.00 | -3.60 | -4.00 | -7.10 | -6.00 | -6.42 | -6.20 | -6.20 | -6.78 | -6.76 | -6.68 |
| ACHN | -4.52 | -4.60 | -5.64 | -5.68 | -5.69 | -4.00 | -3.51 | -4.00 | -8.00 | -7.72 | -7.44 | -7.59 | -7.59 | -6.78 | -6.77 | -6.76 |
| St-4 | -4.59 | -4.72 | -5.99 | -5.73 | -5.81 | -4.00 | -3.58 | -4.00 | -8.00 | -7.65 | -7.45 | -7.60 | -7.60 | -6.80 | -6.80 | -6.72 |
| MKN1 | -4.80 | -4.85 | -6.82 | -5.84 | -5.92 | -4.41 | -4.61 | -4.48 | -8.00 | -7.72 | -7.68 | -7.72 | -7.72 | -7.25 | -7.15 | -6.87 |
| MKN7 | -4.79 | -4.82 | -6.56 | -5.84 | -5.82 | -4.08 | -4.29 | -4.32 | -7.80 | -7.48 | -6.98 | -7.47 | -7.47 | -7.34 | -7.07 | -6.86 |
| MKN28 | -7.18 | -7.21 | -5.82 | -7.09 | -7.13 | -4.00 | -4.40 | -4.18 | -7.70 | -7.42 | -6.77 | -7.37 | -7.37 | -6.84 | -6.82 | -6.87 |
| MKN45 | -6.65 | -6.71 | -6.05 | -7.18 | -6.86 | -4.00 | -4.29 | -4.35 | -7.77 | -7.25 | -6.99 | -7.52 | -7.52 | -6.96 | -6.97 | -6.87 |
| MKN74 | -7.05 | -7.08 | -6.35 | -5.86 | -7.05 | -4.00 | -4.47 | -4.06 | -7.91 | -7.65 | -7.55 | -7.74 | -7.74 | -6.97 | -7.37 | -7.05 |
| DU-145 | -4.47 | -4.70 | -5.68 | -5.68 | -5.65 | -4.00 | -3.57 | -4.00 | -8.00 | -7.64 | -7.59 | -7.71 | -7.71 | -6.90 | -6.89 | -6.70 |
| PC-3 | -4.42 | -4.77 | -5.61 | -5.53 | -5.56 | -4.00 | -3.64 | -4.37 | -8.00 | -7.62 | -7.41 | -7.62 | -7.62 | -6.77 | -6.78 | -6.73 |

Fig. 1.










Fig． 2.

 Nさ INKI－X07

定


[^0]Fig. 3.




[^0]:    $+\frac{5}{2}$这 $\frac{4}{5}$ $\frac{1}{3}$
    $\frac{7}{6} 0$
    0

